var data={"title":"Methotrexate: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Methotrexate: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6555?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">see &quot;Methotrexate: Drug information&quot;</a> and <a href=\"topic.htm?path=methotrexate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Methotrexate: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709040\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Intrathecal and high-dose therapy:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Use only preservative-free methotrexate formulations and diluents for intrathecal and high-dose therapy. Do NOT use formulations or diluents containing preservatives for intrathecal and high-dose therapy because they contain benzyl alcohol.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Appropriate use:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Because of the possibility of serious toxic reactions (which can be fatal), methotrexate should be used only in life threatening neoplastic diseases or in patients with psoriasis or rheumatoid arthritis with severe, recalcitrant, disabling disease which is not adequately responsive to other forms of therapy. Deaths have been reported with the use of methotrexate in the treatment of malignancy, psoriasis, and rheumatoid arthritis. Patients should be closely monitored for bone marrow, liver, lung, skin, and kidney toxicities. Patients should be informed by their physician of the risks involved and be under a physician&rsquo;s care throughout therapy.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">The use of methotrexate high-dose regimens recommended for osteosarcoma requires meticulous care. High-dose regimens of methotrexate injection for other neoplastic diseases are investigational, and a therapeutic advantage has not been established.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Pregnancy:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate has been reported to cause fetal death and/or congenital anomalies. Therefore, it is not recommended for women of childbearing potential unless there is clear medical evidence that the benefits can be expected to outweigh the considered risks. Pregnant women with psoriasis or rheumatoid arthritis should not receive methotrexate. Some products are contraindicated in pregnant women.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Bone marrow suppression:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Unexpectedly severe (sometimes fatal) bone marrow suppression, aplastic anemia, and toxicity have been reported with concomitant administration of methotrexate (usually in high dosage) along with some nonsteroidal anti-inflammatory drugs (NSAIDs).</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Renal impairment:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate elimination is reduced in patients with impaired renal function, ascites, or pleural effusions. Such patients require especially careful monitoring for toxicity, and require dose reduction or, in some cases, discontinuation of methotrexate administration.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hepatotoxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate causes hepatotoxicity, fibrosis, and cirrhosis, but generally only after prolonged use. Acutely, liver enzyme elevations are frequently seen. These are usually transient and asymptomatic, and also do not appear predictive of subsequent hepatic disease. Liver biopsy after sustained use often shows histologic changes, and fibrosis and cirrhosis have been reported; these latter lesions may not be preceded by symptoms or abnormal liver function tests in the psoriasis population. For this reason, periodic liver biopsies are usually recommended for psoriatic patients who are under long-term treatment. Persistent abnormalities in liver function tests may precede appearance of fibrosis or cirrhosis in the rheumatoid arthritis population.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Pneumonitis:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate-induced lung disease, including acute or chronic interstitial pneumonitis, is a potentially dangerous lesion, which may occur acutely at any time during therapy and has been reported at low doses. It is not always fully reversible and fatalities have been reported. Pulmonary symptoms (especially a dry, nonproductive cough) may require interruption of treatment and careful investigation.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Gastrointestinal toxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Unexpectedly severe (sometimes fatal) gastrointestinal toxicity has been reported with concomitant administration of methotrexate (usually in high dosage) along with some nonsteroidal anti-inflammatory drugs (NSAIDs). Diarrhea and ulcerative stomatitis require interruption of therapy; otherwise hemorrhagic enteritis and death from intestinal perforation may occur.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Secondary malignancy:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Malignant lymphomas, which may regress following withdrawal of methotrexate, may occur in patients receiving low-dose methotrexate and, thus, may not require cytotoxic treatment. Discontinue methotrexate first and, if the lymphoma does not regress, appropriate treatment should be instituted.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Tumor lysis syndrome:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Like other cytotoxic drugs, methotrexate may induce tumor lysis syndrome in patients with rapidly growing tumors. Appropriate supportive and pharmacologic measures may prevent or alleviate this complication.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Dermatologic toxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Severe, occasionally fatal skin reactions have been reported following single or multiple doses of methotrexate. Reactions have occurred within days of oral, intramuscular, intravenous, or intrathecal methotrexate administration. Recovery has been reported with discontinuation of therapy.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Opportunistic infections:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Potentially fatal opportunistic infections, especially <i>Pneumocystis jirovecii</i> pneumonia, may occur with methotrexate therapy.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Radiotherapy:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate given concomitantly with radiotherapy may increase the risk of soft tissue necrosis and osteonecrosis.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Severe toxic reactions, including embryo-fetal toxicity</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate can cause the following severe or fatal adverse reactions. Monitor closely and modify dose or discontinue methotrexate as appropriate. Bone marrow suppression; serious infections; renal toxicity and increased toxicity with renal impairment; GI toxicity; hepatic toxicity; pulmonary toxicity; hypersensitivity and dermatologic; methotrexate can cause embryo-fetal toxicity, including fetal death. Use in pJIA is contraindicated in pregnancy. Consider the benefits and risks of methotrexate oral solution and risks to the fetus when prescribing methotrexate oral solution to a pregnant patient with a neoplastic disease. Advise females and males of reproductive potential to use effective contraception during and after treatment with methotrexate oral solution.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Experienced physician (injection):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate should be used only by health care providers whose knowledge and experience include the use of antimetabolite therapy.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194555\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Otrexup;</li>\n      <li>Rasuvo;</li>\n      <li>Rheumatrex [DSC];</li>\n      <li>Trexall;</li>\n      <li>Xatmep</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194556\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Methotrexate Sodium Injection;</li>\n      <li>Metoject</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048583\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Antimetabolite</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antirheumatic, Disease Modifying</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048575\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">see &quot;Methotrexate: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Methotrexate doses between 100 to 500 mg/m<sup>2</sup> <b>may require</b> leucovorin calcium rescue. Methotrexate doses &gt;500 mg/m<sup>2</sup> <b>require</b> leucovorin calcium rescue.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Dosing may be presented as mg/m<sup>2</sup> or mg/<b>kg</b>; verify dosage unit for calculations; extra precautions should be taken. Frequency of dosing is indication specific (generally weekly or daily); patient harm may occur if administered incorrectly; extra precautions should be taken to verify appropriate frequency. For oncology uses, regimens with corresponding dosing and frequency are highly variable and subject to frequent changes; typical dose ranges presented; specific protocols should be consulted.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute lymphoblastic leukemia (ALL) of infancy: </b>Limited data available: <b>Note: </b>Intrathecal therapy is also administered (refer to specific reference for intrathecal dosing used within protocol); other combination chemotherapy variable based on protocol, and phase of treatment; refer to specific protocol: Intensification and Consolidation: Infant (&lt;1 year of age) at diagnosis: IV: 4,000 to 5,000 mg/m<sup>2</sup> over 24 hours every 7 days for 2 doses; specific days depends on protocol phase (Dreyer 2015; Pieters 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute lymphoblastic leukemia (ALL): Note:</b> Intrathecal therapy is also administered (refer to specific reference for intrathecal dosing used within protocol): Limited data available; multiple regimens reported; methotrexate is part of a combination regimen; refer to specific protocols:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Interim maintenanc</i>e:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">High-dose methotrexate: Children and Adolescents IV: 500 mg/m<sup>2</sup> over 30 minutes followed by 4,500 mg/m<sup>2</sup> over 23.5 hours (to complete a total dose of 5,000 mg/m<sup>2</sup> over 24 hours on days 1, 15, 29, and 43 (with leucovorin rescue) (Larsen 2016; Seibel 2008; Winter 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Escalating-dose methotrexate: Children and Adolescents: IV: Initial dose: 100 mg/m<sup>2</sup> then escalate dose by 50 mg/m<sup>2</sup> every 10 days for 5 doses total (Larsen 2016; Seibel 2008; Winter 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Maintenance:</i> Children and Adolescents: Oral: 20 mg/m<sup>2</sup> once weekly (Larsen 2016; Seibel 2008; Winter 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>CNS prophylaxis intrathecal therapy:</i> Infants, Children, and Adolescents: Intrathecal: Age-based dosing: Days of administration vary based on risk status and protocol; refer to institutional protocols or reference for details (Larsen 2016; Lin 2008; Matloub 2006):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&lt;1 year: 6 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">1 to &lt;2 years: 8 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">2 to &lt;3 years: 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">3 to &le;8 years: 12 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&gt;8 years: 15 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>CNS</b>\n      <b> tumors, malignant (medulloblastoma, PNET, ependymoma, brainstem glioma): </b>Limited data available: Head Start II Protocol (Chi 2004): Children &lt;10 years: IV: 400 mg/kg on Day 4 with leucovorin rescue until level less than 0.1 micromolar (&micro;M) every 21 days for 5 cycles (in combination with cisplatin, vincristine, etoposide, and cyclophosmide; then followed by an auto-transplant)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Crohn disease: </b> Limited data available: Children and Adolescents: Oral, SubQ: <b>Note:</b> Should be used in patients intolerant or unresponsive to purine analog therapy (eg, azathioprine, mercaptopurine); use in combination with folic acid supplementation</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">BSA-directed dosing: 15 mg/m<sup>2</sup> once weekly; maximum dose: 25 mg (Mack 1998; Rufo 2012; Sandhu 2010; Turner 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Fixed-dosing (Kliegman 2011; Mack 1998; Turner 2007; Weiss 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">20 to 29 kg: 10 mg once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">30 to 39 kg: 15 mg once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">40 to 49 kg: 20 mg once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ge;50 kg: 25 mg once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Dermatomyositis:</b> Limited data available: Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM or SubQ: 15 to 20 mg/m<sup>2</sup> once a week in combination with corticosteroids and with either folic acid or folinic acid supplementation (Ruperto 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM or SubQ (preferred): Initial: 15 to 20 mg/m<sup>2</sup> <b>or</b> 1 mg/<b>kg</b> (whichever is less) once weekly; maximum dose: 40 mg; used in combination with corticosteroids (Huber 2010; Ramanan 2005, Ruperto 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral (not preferred): Initial: 15 mg/m<sup>2</sup> <b>or</b> 1 mg/<b>kg</b> (whichever is less) once weekly; maximum dose: 40 mg; used in combination with corticosteroids (Huber 2010; Ramanan 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Graft-versus-host disease, acute (aGVHD) prophylaxis:</b> Limited data available: Children and Adolescents: IV: 15 mg/m<sup>2</sup>/dose on day 1 and 10 mg/m<sup>2</sup>/dose on days 3 and 6 after allogeneic transplant (in combination with cyclosporine and prednisone) (Chao 1993; Chao 2000; Ross 1999) or 15 mg/m<sup>2</sup>/dose on day 1 and 10 mg/m<sup>2</sup>/dose on days 3, 6, and 11 after allogeneic transplant (in combination with cyclosporine) (Chao 2000). Leucovorin rescue may be administered according to protocol.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Juvenile idiopathic arthritis (JIA); polyarticular:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">BSA-directed dosing: Children and Adolescents 2 to 16 years: Oral, IM, SubQ: Initial: 10 mg/m<sup>2</sup> once weekly, adjust gradually up to 20 to 30 mg/m<sup>2</sup> once weekly; usual maximum dose: 25 mg; to reduce GI side effects, consider parenteral administration (IM, SubQ) of higher doses (20 to 30 mg/m<sup>2</sup>)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weight-directed dosing: Children and Adolescents: Oral, SubQ: Initial: 0.5 mg/<b>kg</b> once weekly; maximum initial dose: 15 mg; if symptoms worsen or unchanged after 4 weeks, may increase to SubQ: 1 mg/<b>kg</b>; maximum dose: 30 mg (Dewitt 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Meningeal leukemia, prophylaxis or treatment: Note: </b>Frequency and duration of treatment based on protocol; treatment dosing may be a frequency of every 2 to 7 days (based on protocol); for treatment, often used combination with cytarabine and hydrocortisone (triple intrathecal therapy); refer to institutional protocols or references for details<b>.</b> Optimal intrathecal chemotherapy dosing should be based on age rather than on body surface area (BSA); CSF volume correlates with age and not to BSA (Bleyer 1983; Kerr 2001): Infants, Children, and Adolescents: Intrathecal:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&lt;1 year: 6 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">1 to &lt;2 years: 8 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">2 to &lt;3 years: 10 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">3 to &lt;9 years: 12 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&ge;9 years: 15 mg/dose (Larsen 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Non</b>\n      <b>-Hodgkin Lyphoma, B-cell:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Intermediate risk</i>: Limited data available (Goldman 2013; Goldman 2014): <b>Note:</b> Some regimens may include periodic intrathecal methotrexate doses; refer to institution specific protocols or references cited, only intravenous dosing provided. Induction 1 and 2 (COPADM regimen) and Consolidation 1 and 2 (CYM regimen): Children and Adolescents: IV: 3,000 mg/m<sup>2</sup> over 3 hours with leucovorin rescue, combination chemotherapy varied with protocol phase</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>High risk:</i> Limited data available (Cairo 2007): <b>Note:</b> Some regimens may include periodic intrathecal methotrexate doses; refer to institution specific protocols or references cited, only intravenous dosing provided. Infants &ge;6 months, Children, and Adolescents: IV: 8,000 mg/m<sup>2</sup> over 4 hours once followed by leucovorin rescue; specific day of therapy and combination chemotherapy depends on protocol phase and clinical factors (eg, CNS positive)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Non-Hodgkin Lymphoma, T-cell (Anaplastic Large Cell Lymphoma [ALCL])</b>: Limited data available (Reiter 1994; Seideman 2001): NHL-BFM90 protocol: <b>Note:</b> Both intravenous and intrathecal methotrexate dosing were part of protocol; use extra precaution ensuring route and dose. Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Course B: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: 500 mg/m<sup>2</sup> over 24 hours; administer 10% of dose over the first 30 minutes and remaining 90% of dose over 23.5 hours on Day 1 (in combination with dexamethasone, cyclophosphamide, doxorubicin, and triple intrathecal therapy)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Intrathecal: On Day 1; administer 2 hours after the start of the methotrexate IV infusion</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&lt;1 year: 6 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">1 to &lt;2 years: 8 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">2 to 3 years: 10 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&ge;3 years: 12 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i> Course BB:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: 5,000 mg/m<sup>2</sup> over 24 hours; administer 10% of dose over the first 30 minutes and remaining 90% of dose over 23.5 hours on Day 1 (in combination with dexamethasone, cyclophosphamide, vincristine, doxorubicin, and triple intrathecal therapy)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Intrathecal: On Day 1 administer 2 hours after the start of the methotrexate IV infusion; also administered on Day 5. <b>Note:</b> In patients with overt CNS disease and an implantable intraventricular device, presented doses were reduced by 50% (Seideman 2001).</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&lt;1 year: 3 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">1 to &lt;2 years: 4 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">2 to &lt;3 years: 5 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&ge;3 years: 6 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Osteosarcoma:</b> Limited data available: High-dose methotrexate: Children and Adolescents: IV: 12 <b>g</b>/m<sup>2</sup> (maximum dose: 20 <b>g/dose</b>) over 4 hours (followed by leucovorin rescue) for 4 doses during induction (before surgery) at weeks 3, 4, 8, and 9, and for 8 doses during maintenance (after surgery) at weeks 15, 16, 20, 21, 25, 26, 30, and 31 (in combination with doxorubicin and cisplatin) (Meyers 2005); other frequency and duration have also been reported (Ferrari 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Psoriasis, severe; recalcitrant to topical therapy:</b> Limited data available: Children and Adolescents: Oral, SubQ: Usual reported range: 0.2 to 0.4 mg/kg once weekly; reported treatment duration is highly variable: 6 to 178 weeks (Dadlani 2005; deJager 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Scleroderma, localized (juvenile):</b> Limited data available: Infants, Children, and Adolescents: Oral, SubQ (preferred): 1 mg/kg once weekly; maximum dose: 25 mg; alone or in combinations with corticosteroids; duration of therapy: 12 months (Li 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Uveitis, recalcitrant:</b> Limited data available: Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">BSA-directed dosing: Oral, SubQ: Most frequently reported: 15 mg/m<sup>2</sup> once weekly, usual range: 10 to 25 mg/m<sup>2</sup> (Foeldvari 2005; Simonini 2013); the SubQ route may be preferred for patients with GI symptoms, poor bioavailability or doses &gt;15 mg/m<sup>2</sup> (Simonini 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weight-directed dosing: SubQ: 0.5 to 1 mg/<b>kg</b> once weekly; maximum dose: 25 mg (Weiss 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Note:</b> For oncologic uses in obese patients, utilize patient's actual body weight (full weight) for calculation of body surface area- or weight-based dosing, particularly when the intent of therapy is curative; manage regimen-related toxicities in the same manner as for nonobese patients; if a dose reduction is utilized due to toxicity, consider resumption of full weight-based dosing with subsequent cycles, especially if cause of toxicity (eg, hepatic or renal impairment) is resolved (Griggs 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute lymphoblastic leukemia (ALL):</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Meningeal leukemia prophylaxis or treatment:</i> Intrathecal: Manufacturer&rsquo;s labeling: 12 mg (maximum 15 mg/dose) every 2 to 7 days; continue for 1 dose beyond CSF cell count normalization. <b>Note:</b> Optimal intrathecal chemotherapy dosing should be based on age rather than on body surface area (BSA); CSF volume correlates with age and not to BSA (Bleyer 1983; Kerr 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>CALGB 8811 regimen </i>(Larson 1995; combination therapy):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Early intensification: Intrathecal: 15 mg day 1 of early intensification phase, repeat in 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CNS prophylaxis/interim maintenance phase:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Intrathecal: 15 mg day 1, 8, 15, 22, and 29</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Oral: 20 mg/m<sup>2</sup> days 36, 43, 50, 57, and 64</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Prolonged maintenance: Oral: 20 mg/m<sup>2</sup> days 1, 8, 15, and 22 every 4 weeks for 24 months from diagnosis</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Dose-intensive regimen</i> (Kantarjian 2000; combination therapy): IV: 200 mg/m<sup>2</sup> over 2 hours, followed by 800 mg/m<sup>2</sup> over 24 hours beginning day 1 (followed by leucovorin rescue) of even numbered cycles (in combination with cytarabine; alternates with Hyper-CVAD)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>CNS prophylaxis:</i> Intrathecal: 12 mg on day 2 of each cycle; duration depends on risk</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Maintenance:</i> IV: 10 mg/m<sup>2</sup>/day for 5 days every month for 2 years (in combination with prednisone, vincristine, and mercaptopurine)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Ectopic pregnancy:</b> Limited data available: IM:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Single-dose regimen:</i> Methotrexate 50 mg/m<sup>2</sup> on day 1; Measure serum hCG levels on days 4 and 7; if needed, repeat dose on day 7 (Barnhart 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Two-dose regimen:</i> Methotrexate 50 mg/m<sup>2</sup> on day 1; Measure serum hCG levels on day 4 and administer a second dose of methotrexate 50 mg/m<sup>2</sup>; Measure serum hCG levels on day 7 and if needed, administer a third dose of 50 mg/m<sup>2</sup> (Barnhart 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Multidose regimen:</i> Methotrexate 1 mg/kg on day 1; measure serum hCG on day 2; methotrexate 1 mg/<b>kg</b> on day 3; alternate days of therapy with leucovorin (ie, day 2 and day 4); measure serum hCG on day 4; continue up to a total of 4 courses based on hCG concentrations (Barnhart 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Mycosis fungoides (cutaneous T-cell lymphoma):</b> IM, Oral: 5 to 50 mg once weekly or 15 to 37.5 mg twice weekly for early stages (manufacturer's labeling) <b>or</b> 25 mg orally once weekly, may increase to 50 mg once weekly (Zackheim 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Osteosarcoma:</b> Adults &le;30 years: IV: MAP regimen: 12 <b>g</b>/m<sup>2</sup> (maximum dose: 20 <b>g</b>) over 4 hours (followed by leucovorin rescue) for 4 doses during induction (before surgery) at weeks 3, 4, 8, and 9, and for 8 doses during maintenance (after surgery) at weeks 15, 16, 20, 21, 25, 26, 30, and 31 (in combination with doxorubicin and cisplatin) (Meyers 2005); other combinations, intervals, age ranges, and doses (8 to 14 <b>g</b>/m<sup>2</sup>/dose) have been described (with leucovorin rescue), refer to specific reference for details (Bacci 2000; Bacci 2003; Goorin 2003; Le Deley 2007; Meyers 1992; Weiner 1986; Winkler 1988)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Psoriasis: Note:</b> Some experts recommend concomitant daily folic acid (except the day of methotrexate) to reduce hematologic, gastrointestinal, and hepatic adverse events related to methotrexate.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 2.5 to 5 mg/dose every 12 hours for 3 doses given weekly <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral, IM, SubQ: 10 to 25 mg/dose given once weekly; titrate to lowest effective dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> An initial test dose of 2.5 to 5 mg is recommended in patients with risk factors for hematologic toxicity or renal impairment (Kalb 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Rheumatoid arthritis: Note:</b> Some experts recommend concomitant daily folic acid (except the day of methotrexate) to reduce hematologic, gastrointestinal, and hepatic adverse events related to methotrexate.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral (manufacturer's labeling): 7.5 mg once weekly or 2.5 mg every 12 hours for 3 doses per week (dosage exceeding 20 mg per week may cause a higher incidence and severity of adverse events); <i>alternatively,</i> 10 to 15 mg once weekly, increased by 5 mg every 2 to 4 weeks to a maximum of 20 to 30 mg once weekly has been recommended by some experts (Visser 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM, SubQ: 10 to 25 mg once weekly (dosage varies, similar to oral) or 15 mg once weekly (Braun 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for toxicity:</b> Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Nonhematologic toxicity: Diarrhea, stomatitis, or vomiting which may lead to dehydration: Discontinue until recovery</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic toxicity:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Psoriasis, arthritis (JIA): Significant blood count decrease: Discontinue immediately.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oncologic uses: Profound granulocytopenia and fever: Evaluate immediately; consider broad-spectrum parenteral antimicrobial coverage</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling. The following adjustments have been recommended:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oncology doses/uses: Refer to specific protocols for adjustments; the higher oncology doses may require more aggressive dosing adjustments than those recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Nononcology doses/uses: The following have been recommended (Aronoff 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &gt;50 mL/minute/1.73 m<sup>2</sup>: No adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 10 to 50 mL/minute/1.73 m<sup>2</sup>: Administer 50% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;10 mL/minute/1.73 m<sup>2</sup>: Administer 30% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Hemodialysis: Administer 30% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Peritoneal dialysis (PD): Administer 30% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous renal replacement therapy (CRRT): Administer 50% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Aronoff 2007:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &gt;50 mL/minute/1.73 m<sup>2</sup>: No adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 10 to 50 mL/minute: Administer 50% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;10 mL/minute: Avoid use</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Hemodialysis: Administer 50% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Continuous renal replacement therapy (CRRT): Administer 50% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Kintzel 1995:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 46 to 60 mL/minute: Administer 65% of normal dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 31 to 45 mL/minute: Administer 50% of normal dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;30 mL/minute: Avoid use</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Hemodialysis patients with cancer (Janus 2010): Administer 25% of dose after hemodialysis; monitor closely for toxicity</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">High-dose methotrexate, dose-intensive regimen for ALL (200 mg/m<sup>2</sup> over 2 hours, followed by 800 mg/m<sup>2</sup> over 24 hours with leucovorin rescue (Kantarjian 2000):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Serum creatinine &lt;1.5 mg/dL: No dosage adjustment necessary</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Serum creatinine 1.5 to 2 mg/dL: Administer 75% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Serum creatinine &gt;2 mg/dL: Administer 50% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> All patients: There are no dosage adjustments provided in the manufacturer's labeling; use with caution in patients with impaired hepatic function or preexisting hepatic dysfunction. In pediatric oncology patients, refer to specific protocols for adjustments; the higher oncology doses may require more aggressive dosing adjustments. The following adjustments have been recommended in adults (Floyd 2006):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bilirubin 3.1 to 5 mg/dL <b>or</b> transaminases &gt;3 times ULN: Administer 75% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bilirubin &gt;5 mg/dL: Avoid use</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194526\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 250 mg/10 mL (10 mL); 50 mg/2 mL (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g/40 mL (40 mL); 100 mg/4 mL (4 mL); 200 mg/8 mL (8 mL); 250 mg/10 mL (10 mL); 50 mg/2 mL (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Xatmep: 2.5 mg/mL (120 mL) [contains methylparaben sodium, propylparaben sodium]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Auto-injector, Subcutaneous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Otrexup: 7.5 mg/0.4 mL (0.4 mL [DSC]); 10 mg/0.4 mL (0.4 mL); 12.5 mg/0.4 mL (0.4 mL); 15 mg/0.4 mL (0.4 mL); 17.5 mg/0.4 mL (0.4 mL); 20 mg/0.4 mL (0.4 mL); 22.5 mg/0.4 mL (0.4 mL); 25 mg/0.4mL (0.4 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rasuvo: 7.5 mg/0.15 mL (0.15 mL); 10 mg/0.2 mL (0.2 mL); 12.5 mg/0.25 mL (0.25 mL); 15 mg/0.3 mL (0.3 mL); 17.5 mg/0.35 mL (0.35 mL); 20 mg/0.4 mL (0.4 mL); 22.5 mg/0.45 mL (0.45 mL); 25 mg/0.5 mL (0.5 mL); 27.5 mg/0.55 mL (0.55 mL [DSC]); 30 mg/0.6 mL (0.6 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rheumatrex: 2.5 mg [DSC] [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Trexall: 5 mg, 7.5 mg, 10 mg, 15 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2.5 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194511\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048588\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: Often preferred when low doses are being administered; administer on an empty stomach (at least 1 hour before or 2 hours after food or drink except water).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM: May be administered at concentration &le;25 mg/mL; autoinjectors should not be used for IM administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV push: May be administered as slow IV push at a concentration &le;25 mg/mL; some have suggested a rate of &le;10 mg/minute (Gahart 2014)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Bolus IV infusion, or 24-hour continuous infusion: Route and rate of administration depend upon indication and/or protocol; refer to specific references. For high-dose infusion, preservative-free formulation must be used <b>[U.S. Boxed Warning]</b>. Specific dosing schemes vary, but high dose must be followed by leucovorin calcium to prevent toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">SubQ: May be administered SubQ (dependent upon indication and product).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Otrexup and Rasuvo are for once weekly subcutaneous use in the abdomen or thigh; do not inject within 2 inches of the navel or in areas where the skin is tender, bruised, red, scaly, hard or has scars or stretch marks. Patient may self-administer after appropriate training on preparation and administration and with appropriate follow-up monitoring. All schedules should be continually tailored to the individual patient. An initial test dose may be given prior to the regular dosing schedule to detect any extreme sensitivity to adverse effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intrathecal: May be administered intrathecally; must use preservative-free formulation for intrathecal administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132858\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends single gloving for administration of intact tablets or capsules. Double gloving, a protective gown, and (if there is a potential for vomit or spit up) eye/face protection are recommended for administration of an oral liquid/feeding tube administration. For injection preparation, NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs). Double gloving, a gown, and (if dosage form allows) CSTDs are required during injection administration (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194549\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablets: Store between 20&deg;C and 25&deg;C (68&deg;F and 77&deg;F). Protect from light.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection: Store intact vials and autoinjectors between 20&deg;C and 25&deg;C (68&deg;F and 77&deg;F); excursions may be permitted between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F). Protect from light.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: Solution diluted in D5W or NS is stable for 24 hours at room temperature (21&deg;C to 25&deg;C).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intrathecal: Intrathecal dilutions are preservative free and should be used as soon as possible after preparation. After preparation, store intrathecal medications (until use) in an isolated location or container clearly marked with a label identifying as &quot;intrathecal&quot; use only.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral solution: Store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) in a tightly closed container. Patients may store either refrigerated (2&deg;C to 8&deg;C [36&deg;F to 46&deg;F]) or for up to 60 days at room temperature (20&deg;C to 25&deg;C [68&deg;F to 77&deg;F]). Excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Avoid freezing and excessive heat.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048587\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of trophoblastic neoplasms (gestational choriocarcinoma, chorioadenoma destruens, and hydatidiform mole), acute lymphocytic leukemia, osteosarcoma, breast cancer, head and neck cancer (epidermoid), cutaneous T-Cell lymphoma (advanced mycosis fungoides), lung cancer (squamous cell and small cell) [oral, parenteral: FDA approved in pediatric patients (age not specified) and adults]; treatment of meningeal leukemia [parenteral: FDA approved in pediatric patients (age not specified) and adults]; treatment of active polyarticular juvenile idiopathic arthritis (JIA) in patients who have failed to respond to other agents [oral, parenteral (Otrexup): FDA approved in ages 2 to 16 years]; treatment of psoriasis (severe, recalcitrant, disabling) and severe, active rheumatoid arthritis [oral, parenteral (Otrexup): FDA approved in adults]. Has also been used  for the treatment and maintenance of remission in Crohn disease, dermatomyositis, uveitis, scleroderma, ectopic pregnancy, central nervous system tumors (including nonleukemic meningeal cancers), acute promyelocytic leukemia (maintenance treatment), soft tissue sarcoma (desmoid tumors)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194611\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Methotrexate may be confused with mercaptopurine, methylPREDNISolone sodium succinate, metOLazone, metroNIDAZOLE, mitoXANTRONE, PRALAtrexate</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Errors have occurred (resulting in death) when methotrexate was administered as &ldquo;daily&rdquo; dose instead of &ldquo;weekly&rdquo; dose recommended for some indications. The ISMP recommends hospitals use a weekly dosage regimen default for oral methotrexate orders, with a hard stop override requiring verification of appropriate oncology indication; manual systems should require verification of an oncology indication prior to dispensing oral methotrexate for daily administration. Pharmacists should provide patient education for patients discharged on weekly oral methotrexate (ISMP 2014).</p>\n        <p style=\"text-indent:-2em;margin-left:4em;margin-top:2em;\">\n          <i>Intrathecal medication safety:</i> The American Society of Clinical Oncology (ASCO)/Oncology Nursing Society (ONS) chemotherapy administration safety standards (Jacobson 2009) encourage the following safety measures for intrathecal chemotherapy:</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">&bull; Intrathecal medication should not be prepared during the preparation of any other agents</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">&bull; After preparation, keep in an isolated location or container clearly marked with a label identifying as &quot;intrathecal&quot; use only</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">&bull; Delivery to the patient should only be with other medications also intended for administration into the central nervous system</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">MTX is an error-prone abbreviation (mistaken as mitoxantrone or multivitamin)</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Trexall [US] may be confused with Trexol brand name for tramadol [Mexico]; Truxal brand name for chlorprothixene [multiple international markets]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194607\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Adverse reactions vary by route and dosage.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Arterial thrombosis, cerebral thrombosis, chest pain, deep vein thrombosis, hypotension, pericardial effusion, pericarditis, plaque erosion (psoriasis), pulmonary embolism, retinal thrombosis, thrombophlebitis, vasculitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Abnormal cranial sensation, brain disease, chemical arachnoiditis (intrathecal; acute), chills, cognitive dysfunction (has been reported at low dosage), dizziness, drowsiness, fatigue, headache (pJIA), leukoencephalopathy (intravenous administration after craniospinal irradiation or repeated high-dose therapy; may be chronic), malaise, mood changes (has been reported at low dosage), neurological signs and symptoms (at high dosages; including confusion, hemiparesis, transient blindness, seizures, and coma), severe neurotoxicity (reported with unexpectedly increased frequency among pediatric patients with acute lymphoblastic leukemia who were treated with intermediate-dose intravenous methotrexate), speech disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Acne vulgaris, alopecia, burning sensation of skin (psoriasis), dermal ulcer, dermatitis (rheumatoid arthritis), diaphoresis, ecchymoses, erythema multiforme, erythematous rash, exfoliative dermatitis, furunculosis, hyperpigmentation, hypopigmentation, pruritus (rheumatoid arthritis), skin abnormalities related to radiation recall, skin necrosis, skin photosensitivity, skin rash, Stevens-Johnson syndrome, telangiectasia, toxic epidermal necrolysis, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Decreased libido, decreased serum albumin, diabetes mellitus, gynecomastia, menstrual disease</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal distress, anorexia, aphthous stomatitis, diarrhea, enteritis, gastrointestinal hemorrhage, gingivitis, hematemesis, intestinal perforation, melena, nausea and vomiting, stomatitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Azotemia, cystitis, defective oogenesis, defective spermatogenesis, dysuria, hematuria, impotence, infertility, oligospermia, pancreatitis, proteinuria, severe renal disease, vaginal discharge</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Agranulocytosis, anemia, aplastic anemia, bone marrow depression (nadir: 7-10 days), decreased hematocrit, eosinophilia, gastric ulcer, hypogammaglobulinemia, leukopenia (WBC &lt;3000/mm<sup>3</sup>), lymphadenopathy, lymphoma, lymphoproliferative disorder, neutropenia, non-Hodgkin&rsquo;s lymphoma (in patients receiving low-dose oral methotrexate), pancytopenia (rheumatoid arthritis), thrombocytopenia (rheumatoid arthritis; platelet count &lt;100,000/mm<sup>3</sup>), tumor lysis syndrome</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Cirrhosis (chronic therapy), hepatic failure, hepatic fibrosis (chronic therapy), hepatitis (acute), hepatotoxicity, increased liver enzymes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Anaphylactoid reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Cryptococcosis, cytomegalovirus disease (including cytomegaloviral pneumonia, sepsis, nocardiosis), herpes simplex infection, herpes zoster, histoplasmosis, infection, vaccinia (disseminated; following smallpox immunization)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, myalgia, myelopathy (subacute), osteonecrosis (with radiotherapy), osteoporosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blurred vision, conjunctivitis, eye pain, visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Renal failure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Chronic obstructive pulmonary disease, cough, epistaxis, interstitial pneumonitis (rheumatoid arthritis), pharyngitis, pneumonia (including <i>Pneumocystis jirovecii</i>), pulmonary alveolitis, pulmonary disease, pulmonary fibrosis, respiratory failure, upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever, nodule, tissue necrosis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Acute respiratory distress (Morgan 2011), bone fracture (stress), cerebrovascular accident (Morgan 2011), mesenteric ischemia (acute; Morgan 2011)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194534\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Known hypersensitivity to methotrexate or any component of the formulation; breast-feeding</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Additional contraindications for patients with psoriasis, rheumatoid arthritis or polyarticular-course juvenile idiopathic arthritis: Pregnancy, alcoholism, alcoholic liver disease or other chronic liver disease, immunodeficiency syndromes (overt or laboratory evidence); preexisting blood dyscrasias (eg, bone marrow hypoplasia, leukopenia, thrombocytopenia, significant anemia)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194515\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute renal failure: May cause renal damage leading to acute renal failure, especially with high-dose methotrexate; monitor renal function and methotrexate levels closely, maintain adequate hydration and urinary alkalinization. Use with caution in osteosarcoma patients treated with high-dose methotrexate in combination with nephrotoxic chemotherapy (eg, cisplatin).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: <b>[US Boxed Warning]: Unexpectedly severe (sometimes fatal) bone marrow suppression and aplastic anemia have been reported with concomitant administration of methotrexate (usually in high dosage) along with some nonsteroidal anti-inflammatory drugs (NSAIDs);</b> anemia, pancytopenia, leukopenia, neutropenia, and/or thrombocytopenia may occur. Monitor blood counts. Use with caution in patients with preexisting bone marrow suppression. Discontinue treatment (immediately) in rheumatoid arthritis (RA) or psoriasis if a significant decrease in hematologic components is noted.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS effects: May cause neurotoxicity. Leukoencephalopathy has been reported (case reports), usually in patients who have received cranial irradiation and IV methotrexate. Chronic leukoencephalopathy has been reported with high-dose methotrexate (with leucovorin rescue and even without cranial irradiation) and with intrathecal methotrexate; discontinuing methotrexate does not always result in complete recovery; may be progressive and fatal. Serious neurotoxicity, including generalized and focal seizures has occurred (usually in pediatric ALL patients receiving intermediate-dose (1 g/m<sup>2</sup> IV methotrexate); leukoencephalopathy and/or microangiopathic calcifications were noted on diagnostic imaging studies in symptomatic patients. A transient acute stroke-like encephalopathy has been observed, usually with high-dose regimens; manifestations may include confusion, hemiparesis, transient blindness, seizure, and coma. Chemical arachnoiditis (headache, back pain, nuchal rigidity, fever) and myelopathy may result from intrathecal administration. May cause dizziness and fatigue; may affect the ability to drive or operate heavy machinery.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dermatologic toxicity: <b>Severe, occasionally fatal skin reactions have been reported following single or multiple doses of methotrexate. Reactions have occurred within days of oral, intramuscular, intravenous, or intrathecal methotrexate administration. Recovery has been reported with discontinuation of therapy.</b> Severe dermatologic reactions have included toxic epidermal necrolysis, Stevens-Johnson syndrome, exfoliative dermatitis, skin necrosis, and erythema multiforme; discontinue methotrexate if severe reactions occur. Radiation recall dermatitis and sunburn may be precipitated by methotrexate administration. Psoriatic lesions may be worsened by concomitant exposure to ultraviolet radiation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fertility: May cause impairment of fertility, oligospermia, and menstrual dysfunction; it is not known if fertility impairment is reversible.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal toxicity: <b>[US Boxed Warning]: Gastrointestinal toxicity may occur (may be unexpectedly severe, usually occurs with high doses along with concomitant use of some NSAIDs); diarrhea and ulcerative stomatitis may require treatment interruption; otherwise hemorrhagic enteritis and death from intestinal perforation may occur.</b> Diarrhea or stomatitis may also require discontinuation. Use with caution in patients with peptic ulcer disease or ulcerative colitis; the risk of GI adverse effects may be increased. In children, doses &ge;12 g/m<sup>2</sup> (IV) are associated with a high emetic potential; doses &ge;250 mg/m<sup>2</sup> (IV) in adults and children are associated with moderate emetic potential (Dupuis 2011). Antiemetics may be recommended to prevent nausea and vomiting.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: <b>[US Boxed Warning]: Methotrexate causes hepatotoxicity, fibrosis, and cirrhosis, but generally only after prolonged use. Acutely, liver enzyme elevations are frequently seen. These are usually transient and asymptomatic, and also do not appear predictive of subsequent hepatic disease. Liver biopsy after sustained use often shows histologic changes, and fibrosis and cirrhosis have been reported; these latter lesions often are not preceded by symptoms or abnormal liver function tests in the psoriasis population. For this reason, periodic liver biopsies are usually recommended for psoriatic patients who are under long-term treatment. Persistent abnormalities in liver function tests may precede appearance of fibrosis or cirrhosis in the rheumatoid arthritis population. </b> Risk is related to cumulative dose (&ge;1.5 g) and prolonged exposure. Monitor closely (with liver function tests, including serum albumin) for liver toxicities. Liver enzyme elevations may be noted, but may not be predictive of hepatic disease in long term treatment for psoriasis (but generally is predictive in RA treatment). Discontinue methotrexate with moderate to severe change in liver biopsy. Risk factors for hepatotoxicity include history of above moderate ethanol consumption, persistent abnormal liver chemistries, history of chronic liver disease (including hepatitis B or C), family history of inheritable liver disease, diabetes, obesity, hyperlipidemia, lack of folate supplementation during methotrexate therapy, cumulative methotrexate dose exceeding 1.5 g, continuous daily methotrexate dosing, history of significant exposure to hepatotoxic drugs, and advanced age. Use with caution with preexisting liver impairment; may require dosage reduction. Use with caution when used with other hepatotoxic agents (azathioprine, retinoids, sulfasalazine).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Anaphylaxis may occur; if anaphylaxis or other serious hypersensitivity reaction occurs, discontinue methotrexate immediately and institute appropriate management.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infections: <b>[US Boxed Warning]: Immune suppression may lead to potentially fatal opportunistic infections, including </b><i><b>Pneumocystis jirovecii</b></i><b> pneumonia (PCP).</b> Methotrexate use increases the risk for developing life-threatening or fatal bacterial, fungal, or viral infections, including invasive fungal infections, hepatitis B reactivation, tuberculosis (primary infection or reactivation), disseminated herpes zoster infection and/or cytomegalovirus infection. Use methotrexate with extreme caution in patients with an active infection (contraindicated in patients with immunodeficiency syndrome). Monitor for signs/symptoms of infection during and after treatment; manage promptly if infections occurs. Dose reduction or discontinuation may be necessary for serious infection.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pneumonitis: <b>[US Boxed Warning]: Methotrexate-induced lung disease, including acute or chronic interstitial pneumonitis, is a potentially dangerous lesion, which may occur acutely at any time during therapy and has been reported at low doses. It is not always fully reversible and fatalities have been reported. Pulmonary symptoms (especially a dry, nonproductive cough) may require interruption of treatment and careful investigation.</b> Pulmonary symptoms may occur at any time during therapy and at any dosage; monitor closely for pulmonary symptoms, particularly dry, nonproductive cough. Other potential symptoms include fever, dyspnea, hypoxemia, or pulmonary infiltrate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Secondary malignancy: <b>[US Boxed Warning]: Malignant lymphomas, which may regress following withdrawal of methotrexate, may occur in patients receiving low-dose methotrexate and, thus, may not require cytotoxic treatment. Discontinue methotrexate first and, if the lymphoma does not regress, appropriate treatment should be instituted. </b>Other secondary tumors have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tumor lysis syndrome: <b>[US Boxed Warning]: Tumor lysis syndrome may occur in patients with high tumor burden; appropriate supportive and pharmacologic measures may prevent or alleviate tumor lysis syndrome. </b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ascites/pleural effusions:<b> [US Boxed Warning]: Elimination is reduced in patients with ascites and/or pleural effusions;</b> resulting in prolonged half-life and toxicity; may require dose reduction or discontinuation. Monitor closely for toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with preexisting liver impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Peptic ulcer disease: Use with caution in patients with peptic ulcer disease; diarrhea and stomatitis may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: <b>[US Boxed Warning]: Methotrexate elimination is reduced in patients with renal impairment; monitor closely for toxicity; may require dose reduction or, in some cases, discontinuation of methotrexate administration.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ulcerative colitis: Use with caution in patients with ulcerative colitis; diarrhea and stomatitis may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxic agents: Use caution when used with other hepatotoxic agents (azathioprine, retinoids, sulfasalazine).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Mercaptopurine: Methotrexate may increase the levels and effects of mercaptopurine; may require dosage adjustments.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nephrotoxic chemotherapy: Use with caution in osteosarcoma patients treated with high-dose methotrexate in combination with nephrotoxic chemotherapy (eg, cisplatin).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; NSAIDs: Do not administer NSAIDs prior to or during high dose methotrexate therapy; may increase and prolong serum methotrexate levels. Doses used for psoriasis may still lead to unexpected toxicities; use with caution when administering NSAIDs or salicylates with lower doses of methotrexate for RA.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Proton pump inhibitors: Concomitant use of proton pump inhibitors with methotrexate (primarily high-dose methotrexate) may elevate and prolong serum methotrexate levels and metabolite (hydroxymethotrexate) levels (based on case reports and pharmacokinetic studies). May lead to toxicities; use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vaccines: Immunization may be ineffective during methotrexate treatment. Immunization with live vaccines is not recommended; cases of disseminated vaccinia infections due to live vaccines have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vitamins: Vitamins containing folate may decrease response to systemic methotrexate; folate deficiency may increase methotrexate toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use caution and monitor closely in the elderly; increased risk of toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pregnancy: <b>[US Boxed Warning]: Methotrexate has been reported to cause fetal death and/or congenital abnormalities. Methotrexate is not recommended for women of childbearing potential unless there is clear medical evidence that the benefits can be expected to outweigh the considered risks. Pregnant women with psoriasis or rheumatoid arthritis should not receive methotrexate. Some products are contraindicated in pregnant women. </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Radiotherapy recipients: <b>[US Boxed Warning]: Concomitant methotrexate administration with radiotherapy may increase the risk of soft tissue necrosis and osteonecrosis.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Intrathecal and high-dose therapy: <b> [US Boxed Warnings]: Use only preservative-free methotrexate formulations and diluents for intrathecal and high-dose therapy. Do NOT use formulations or diluents containing preservatives for intrathecal and high-dose therapy because they contain benzyl alcohol.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Administration schedules: Errors have occurred (some resulting in death) when methotrexate was administered as a &ldquo;daily&rdquo; dose instead of a &ldquo;weekly&rdquo; dose intended for some indications. The ISMP Targeted Medication Safety Best Practices for Hospitals recommends hospitals use a weekly dosage regimen default for oral methotrexate orders, with a hard stop override requiring verification of appropriate oncology indication; manual systems should require verification of an oncology indication prior to dispensing oral methotrexate for daily administration. Pharmacists should provide patient education for patients discharged on weekly oral methotrexate; education should include written leaflets that contain clear instructions about the weekly dosing schedule and explain the danger of taking extra doses (ISMP 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: <b>[US Boxed Warnings]: Because of the possibility of serious toxic reactions (which can be fatal), methotrexate should be used only in life threatening neoplastic diseases or in patients with psoriasis or rheumatoid arthritis with severe, recalcitrant, disabling disease which is not adequately responsive to other forms of therapy. Deaths have been reported with the use of methotrexate in the treatment of malignancy, psoriasis, and rheumatoid arthritis. Patients should be closely monitored for bone marrow, liver, lung, skin, and kidney toxicities. Patients should be informed by their physician of the risks involved and be under a physician&rsquo;s care throughout therapy. The use of methotrexate high-dose regimens recommended for osteosarcoma requires meticulous care. High-dose regimens of methotrexate injection for other neoplastic diseases are investigational, and a therapeutic advantage has not been established. </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced physician: <b>[US Boxed Warnings]: Should be administered under the supervision of a physician experienced in the use of antimetabolite therapy.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Intrathecal safety: When used for intrathecal administration, should not be prepared during the preparation of any other agents. After preparation, store intrathecal medications in an isolated location or container clearly marked with a label identifying as &quot;intrathecal&quot; use only. Delivery of intrathecal medications to the patient should only be with other medications intended for administration into the central nervous system (Jacobson 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Methotrexate overexposure: Glucarpidase is an enzyme that rapidly hydrolyzes extracellular methotrexate into inactive metabolites, allowing for a rapid reduction of methotrexate concentrations. Glucarpidase may be used for methotrexate overexposure; it is approved for the treatment of toxic plasma methotrexate concentrations (&gt;1 micromole/L) in patients with delayed clearance due to renal impairment. Refer to Glucarpidase monograph.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9837690\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of BCRP/ABCG2, OAT3, OATP1B1/SLCO1B1, P-glycoprotein/ABCB1</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194520\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12595&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acitretin: May enhance the hepatotoxic effect of Methotrexate.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alitretinoin (Systemic): May enhance the hepatotoxic effect of Methotrexate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bile Acid Sequestrants: May decrease the absorption of Methotrexate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cephalothin: May diminish the therapeutic effect of Methotrexate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ciprofloxacin (Systemic): May increase the serum concentration of Methotrexate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): May increase the serum concentration of Methotrexate. This may result in nausea, vomiting, oral ulcers, hepatotoxicity and/or nephrotoxicity. Methotrexate may increase the serum concentration of CycloSPORINE (Systemic). This may result in nephrotoxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexketoprofen: May increase the serum concentration of Methotrexate. Management: Concurrent use of dexketoprofen with methotrexate doses of 15 mg/week or more is inadvisable.  Use with lower methotrexate doses should only be performed with caution and increased monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diethylamine Salicylate: May increase the serum concentration of Methotrexate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Methotrexate. Methotrexate may enhance the adverse/toxic effect of Dipyrone. Specifically, the risk for agranulocytosis and pancytopenia may be increased.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eltrombopag: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Foscarnet: May enhance the nephrotoxic effect of Methotrexate.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin-Phenytoin: Methotrexate may decrease the serum concentration of Fosphenytoin-Phenytoin. Fosphenytoin-Phenytoin may increase the serum concentration of Methotrexate. Specifically, fosphenytoin-phenytoin may displace methotrexate from serum proteins, increasing the concentration of free, unbound drug. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gemfibrozil: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates. See separate drug interaction monographs for agents listed as exceptions.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: May increase the serum concentration of Methotrexate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Methotrexate may enhance the adverse/toxic effect of Leflunomide. Particular concerns are an increased risk of pancytopenia and/or hepatotoxicity. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">LevETIRAcetam: May increase the serum concentration of Methotrexate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: Methotrexate may diminish the therapeutic effect of Loop Diuretics. Loop Diuretics may increase the serum concentration of Methotrexate. Methotrexate may increase the serum concentration of Loop Diuretics.  Management: Monitor for increased methotrexate and/or loop diuretic levels/toxicity with concomitant use of these agents and monitor for decreased therapeutic effects of loop diuretics. Methotrexate and/or loop diuretic dose reductions may be necessary.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. Lumacaftor may increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mipomersen: May enhance the hepatotoxic effect of Methotrexate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May increase the serum concentration of Methotrexate. Management: Alternative anti-inflammatory therapy should be considered whenever possible, especially if the patient is receiving higher, antineoplastic doses of methotrexate.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Penicillins: May increase the serum concentration of Methotrexate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Methotrexate. Management: Avoid concomitant use of probenecid and methotrexate if possible.  If used together, consider lower methotrexate doses and monitor for evidence of methotrexate toxicity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Proton Pump Inhibitors: May increase the serum concentration of Methotrexate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pyrimethamine: May enhance the adverse/toxic effect of Methotrexate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May increase the serum concentration of Methotrexate. Salicylate doses used for prophylaxis of cardiovascular events are not likely to be of concern.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sapropterin: Methotrexate may decrease the serum concentration of Sapropterin. Specifically, methotrexate may decrease tissue concentrations of tetrahydrobiopterin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SulfaSALAzine: May enhance the hepatotoxic effect of Methotrexate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfonamide Antibiotics: May enhance the adverse/toxic effect of Methotrexate. Management: Consider avoiding concomitant use of methotrexate and either sulfamethoxazole or trimethoprim. If used concomitantly, monitor for the development of signs and symptoms of methotrexate toxicity (eg, bone marrow suppression).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tegafur: Methotrexate may enhance the adverse/toxic effect of Tegafur. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teriflunomide: May increase the serum concentration of OAT3 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teriflunomide: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Methotrexate may increase the serum concentration of Theophylline Derivatives. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Methotrexate may enhance the immunosuppressive effect of Tofacitinib.  Management: Avoid the use of tofacinib in combination with potent immunosuppressive methotrexate-containing regimens.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trimethoprim: May enhance the adverse/toxic effect of Methotrexate. Management: Consider avoiding concomitant use of methotrexate and either sulfamethoxazole or trimethoprim. If used concomitantly, monitor for the development of signs and symptoms of methotrexate toxicity (e.g., bone marrow suppression).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Methotrexate may enhance the adverse/toxic effect of Vaccines (Live). Methotrexate may diminish the therapeutic effect of Vaccines (Live).  Management: Low-dose methotrexate (0.4 mg/kg/week or less) is not considered sufficiently immunosuppressive to create vaccine safety concerns. Higher doses of methotrexate should be avoided.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194552\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;display:inline\">Methotrexate peak serum levels may be decreased if taken with food. Milk-rich foods may decrease methotrexate absorption. Management: Administer without regard to food.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194522\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">X (psoriasis, rheumatoid arthritis) (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194538\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>[US Boxed Warning]: Some products are contraindicated in pregnant women. Methotrexate has been reported to cause fetal death and/or congenital abnormalities. Methotrexate is not recommended for women of childbearing potential unless there is clear medical evidence that the benefits can be expected to outweigh the considered risks. Pregnant women with psoriasis or rheumatoid arthritis should not receive methotrexate.</b> Studies in animals and pregnant women have shown evidence of fetal abnormalities; therefore, the manufacturer classifies methotrexate as pregnancy category X (for psoriasis or RA). A pattern of congenital malformations associated with maternal methotrexate use is referred to as the aminopterin/methotrexate syndrome. Features of the syndrome include CNS, skeletal, and cardiac abnormalities. Low birth weight and developmental delay have also been reported. The use of methotrexate may impair fertility and cause menstrual irregularities or oligospermia during treatment and following therapy. It is not known if fertility impairment is reversible. Methotrexate is approved for the treatment of trophoblastic neoplasms (gestational choriocarcinoma, chorioadenoma destruens, and hydatidiform mole) and has been used for the medical management of ectopic pregnancy and the medical management of abortion. Pregnancy should be excluded prior to therapy in women of childbearing potential. Use for the treatment of neoplastic diseases only when the potential benefit to the mother outweighs the possible risk to the fetus. Pregnancy should be avoided for &ge;3 months following treatment in male patients and at least 6 months and &ge;1 ovulatory cycle in female patients. A registry is available for pregnant women exposed to autoimmune medications including methotrexate. For additional information contact the Organization of Teratology Information Specialists, OTIS Autoimmune Diseases Study, at 877-311-8972.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048582\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Laboratory tests should be performed on day 5 or day 6 of the weekly methotrexate cycle (eg, psoriasis, RA, JIA) to detect the leukopenia nadir and to avoid elevated LFTs 1 to 2 days after taking dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indication-specific recommendations: <b>Note:</b> Additional recommendations may vary based upon patient age and specific protocols (refer to specific references); for all pediatric patients receiving long-term therapy (ie, chronic disease), growth parameters should also be monitored.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Psoriasis:</b> CBC with differential and platelets (baseline, 7 to 14 days after initiating therapy or dosage increase, every 2 to 4 weeks for first few months, then every 1 to 3 months); BUN and serum creatinine (baseline and every 2 to 3 months); consider PPD for latent TB screening (baseline); LFTs (baseline, monthly for first 6 months, then every 1 to 2 months); chest x-ray (baseline if underlying lung disease); pulmonary function test (if methotrexate-induced lung disease suspected)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Liver biopsy:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patients <b>with</b> risk factors for hepatotoxicity: Baseline or after 2 to 6 months of therapy and with each 1 to 1.5 g cumulative dose interval in adults</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patients <b>without</b> risk factors for hepatotoxicity: If persistent elevations in 5 of 9 AST levels during a 12-month period, or decline of serum albumin below the normal range with normal nutritional status. In adults, consider biopsy after cumulative dose of 3.5 to 4 g and after each additional 1.5 g.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Juvenile idiopathic arthritis:</b> Children and Adolescents: PPD screening (baseline and annually); CBC with differential and platelets, C-reactive protein, ESR, ferritin, and LDH [baseline, at follow-up visits (1 to 2 weeks, 1, 2, 6, and 9 months] and with any treatment change (DeWitt 2012).  Also based on adult recommendations in RA, consider serum creatinine and LFTs (baseline then every 2 to 4 weeks for initial 3 months of therapy, then every 8 to 12 weeks for 3 to 6 months of therapy and then every 12 weeks after 6 months of therapy) and liver biopsy: Baseline (if persistent abnormal baseline LFTs, history of alcoholism, or chronic hepatitis B or C) or during treatment if persistent LFT elevations (6 of 12 tests abnormal over 1 year or 5 of 9 results when LFTs performed at 6-week intervals)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Rheumatoid arthritis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CBC with differential and platelets, serum creatinine and LFTs (baseline, then every 2 to 4 weeks for initial 3 months of therapy, then every 8 to 12 weeks for 3 to 6 months of therapy and then every 12 weeks after 6 months of therapy); chest x-ray (baseline); pulmonary function test (if methotrexate-induced lung disease suspected); hepatitis B or C testing (baseline)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Liver biopsy: Baseline (if persistent abnormal baseline LFTs, history of alcoholism, or chronic hepatitis B or C) or during  treatment if persistent LFT elevations (6 of 12 tests abnormal over 1 year or 5 of 9 results when LFTs performed at 6-week intervals)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cancer:</b> Baseline and frequently during treatment: CBC with differential and platelets, serum creatinine, BUN, LFTs; chest x-ray (baseline); serum methotrexate concentrations and urine pH (with high-dose therapy); pulmonary function test (if methotrexate-induced lung disease suspected)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Crohn disease:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents: In pediatric trials, frequency of monitoring varied with study protocol and duration; may vary based on clinical status and concurrent medication; consider the following: CBC with differential and platelets, LFTs, C-reactive protein, and ESR (baseline, then  every 2 to 4 weeks during initial 8 to 12 weeks of therapy, then every 4 to 12 weeks while on therapy); chest x-ray and PFTs (annually) (Mack 1998; Sandhu 2010; Turner 2007; Weiss 2009). Also, based on adult recommendations for Crohn disease, consider serum creatinine (baseline, then every 2 to 4 weeks for initial 3 months of therapy, then every 8 to 12 weeks for 3 to 6 months of therapy and then every 12 weeks after 6 months of therapy), hepatitis B or C testing (baseline) and liver biopsy: Baseline (if persistent abnormal baseline LFTs, history of alcoholism, or chronic hepatitis B or C) or during treatment if persistent LFT elevations (6 of 12 tests abnormal over 1 year or 5 of 9 results when LFTs performed at 6-week intervals).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults: CBC with differential and platelets, serum creatinine and LFTs (baseline then every 2 to 4 weeks for initial 3 months of therapy, then every 8 to 12 weeks for 3 to 6 months of therapy and then every 12 weeks after 6 months of therapy); chest x-ray (baseline); pulmonary function test (if methotrexate-induced lung disease suspected); hepatitis B or C testing (baseline) and liver biopsy: Baseline (if persistent abnormal baseline LFTs, history of alcoholism, or chronic hepatitis B or C) or during treatment if persistent LFT elevations (6 of 12 tests abnormal over 1 year or 5 of 9 results when LFTs performed at 6-week intervals)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Ectopic pregnancy:</b> Prior to therapy, measure serum hCG, CBC with differential, liver function tests, serum creatinine. Serum hCG concentrations should decrease between treatment days 4 and 7. If hCG decreases by &gt;15%, additional courses are not needed; however, continue to measure hCG weekly until no longer detectable. If &lt;15% decrease is observed, repeat dose per regimen (Barnhart 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1048586\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Therapeutic levels: Variable; toxic concentration: Variable; therapeutic range is dependent upon therapeutic approach</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">High-dose regimens produce drug levels that are between 0.1 to 1 micromole/L 24 to 72 hours after drug infusion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Toxic: Low-dose therapy: &gt;0.2 micromole/L; high-dose therapy: &gt;1 micromole/L</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194514\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate is a folate antimetabolite that inhibits DNA synthesis, repair, and cellular replication. Methotrexate irreversibly binds to and inhibits dihydrofolate reductase, inhibiting the formation of reduced folates, and thymidylate synthetase, resulting in inhibition of purine and thymidylic acid synthesis, thus interfering with DNA synthesis, repair, and cellular replication. Methotrexate is cell cycle specific for the S phase of the cycle. Actively proliferative tissues are more susceptible to the effects of methotrexate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The mechanism in the treatment of rheumatoid arthritis and polyarticular-course juvenile idiopathic arthritis is unknown, but may affect immune function. In psoriasis, methotrexate is thought to target rapidly proliferating epithelial cells in the skin.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">In Crohn disease, it may have immune modulator and anti-inflammatory activity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194533\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Antirheumatic: 3 to 6 weeks; additional improvement may continue longer than 12 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Highly variable; dose dependent; decreased absorption at higher doses (pediatric patients: &gt;40 mg/m<sup>2</sup>; adult patients: &gt;80 mg/m<sup>2</sup>); possibly due to saturation effect</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM injection: Complete</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Penetrates slowly into third space fluids (eg, pleural effusions, ascites), exits slowly from these compartments (slower than from plasma); sustained concentrations retained in kidney and liver</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">V<sub>d</sub>: IV: 0.18 L/kg (initial); 0.4 to 0.8 L/kg (steady state)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: ~50%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Partially metabolized by intestinal flora (after oral administration) to DAMPA by carboxypeptidase; hepatic aldehyde oxidase converts methotrexate to 7-hydroxy methotrexate; polyglutamates are produced intracellularly and are just as potent as methotrexate; their production is dose- and duration-dependent and they are slowly eliminated by the cell once formed. Polyglutamated forms can be converted back to methotrexate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Oral: Children: Highly variable: 23% to 95%; Adults: Low doses (&le;30 mg/m<sup>2</sup>): ~60%; in general, bioavailability is dose dependent and decreases as the dose increases (especially at doses &gt;80 mg/m<sup>2</sup> [&gt;40 mg/m<sup>2</sup> in pediatric patients])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children: ALL: 0.7 to 5.8 hours (dose range: 6.3 to 30 mg/m<sup>2</sup>); pJIA: 0.9 to 2.3 hours (dose range: 3.75 to 26.2 mg/m<sup>2</sup>)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Low dose: 3 to 10 hours; High dose: 8 to 15 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak, serum: Oral: Children: 0.7 to 4 hours (reported for a 15 mg/m<sup>2</sup> dose); Adults: 1 to 2 hours; IM: Children and Adults: 30 to 60 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Dose and route dependent; IV: Urine (80% to 90% as unchanged drug; 5% to 7% as 7-hydroxy methotrexate); feces (&lt;10%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194537\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Methotrexate Sodium (PF) Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g/40mL (40 mL): $41.16</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/2 mL (2 mL): $4.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/4 mL (4 mL): $7.32</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mg/8 mL (8 mL): $10.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg/10 mL (10 mL): $11.17</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Methotrexate Sodium Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg/2 mL (2 mL): $8.59</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 mg/10 mL (10 mL): $40.31</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Xatmep Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg/mL (120 mL): $2,275.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Methotrexate Sodium Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $76.32</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Auto-injector</b> (Otrexup Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/0.4 mL (0.4 mL): $194.94</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12.5 mg/0.4 mL (0.4 mL): $194.94</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg/0.4 mL (0.4 mL): $194.94</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">17.5 mg/0.4 mL (0.4 mL): $194.94</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/0.4 mL (0.4 mL): $194.94</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">22.5 mg/0.4 mL (0.4 mL): $194.94</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg/0.4 mL (0.4 mL): $194.94</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Auto-injector</b> (Rasuvo Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7.5 mg/0.15 mL (0.15 mL): $141.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/0.2 mL (0.2 mL): $141.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12.5 mg/0.25 mL (0.25 mL): $141.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg/0.3 mL (0.3 mL): $141.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">17.5 mg/0.35ml (0.35 mL): $141.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/0.4 mL (0.4 mL): $141.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">22.5 mg/0.45ml (0.45 mL): $141.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg/0.5 mL (0.5 mL): $141.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg/0.6 mL (0.6 mL): $141.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Methotrexate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg (100): $356.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Methotrexate Sodium Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg (36): $145.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Trexall Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (30): $498.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">7.5 mg (30): $747.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (30): $996.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (30): $1,494.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F194540\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Abitrexate (IL, SG, TH, TW, ZW);</li>\n      <li>Alltrex (LK);</li>\n      <li>Artrait (AR, PE);</li>\n      <li>Atrexel (MX);</li>\n      <li>Bertanel (ES);</li>\n      <li>Biotrexate (IN);</li>\n      <li>Brimexate (IT);</li>\n      <li>Canceren (KR);</li>\n      <li>Cytotrex (LK);</li>\n      <li>Ebetrex (LV);</li>\n      <li>Ebetrexat (AE, AT, BG, HR, LB);</li>\n      <li>Emthexat (SE);</li>\n      <li>Emthexate (AT, BE, GR, ID, JO, KW, MY, NL, PH, PK, PT, TH, TR, TW);</li>\n      <li>Emthexate PF (KR);</li>\n      <li>Emthrxate (SI);</li>\n      <li>Hytas (BR);</li>\n      <li>Imutrex (LK);</li>\n      <li>Lantarel (DE);</li>\n      <li>Ledertrexate (BE, FR, LU, MX, NZ, PT);</li>\n      <li>Maxtrex (GB);</li>\n      <li>Medsatrexate (MX);</li>\n      <li>Meisusheng (CN);</li>\n      <li>Merox-50 (ET);</li>\n      <li>Metex (LV);</li>\n      <li>Methoblastin (AU, NZ);</li>\n      <li>Methofill (IE);</li>\n      <li>Methotrexat (HR);</li>\n      <li>Methotrexat Bigmar (CH);</li>\n      <li>Methotrexat Ebewe (HU);</li>\n      <li>Methotrexat Farmos (CH);</li>\n      <li>Methotrexat Lachema (HU);</li>\n      <li>Methotrexat Lederle (CH);</li>\n      <li>Methotrexat Teva (CH);</li>\n      <li>Methotrexate (AU, HK, ID, IL, MY, PH, TH, TW);</li>\n      <li>Methotrexate Faulding (SE);</li>\n      <li>Methotrexate Pharmacia (SE);</li>\n      <li>Methotrexate Wyeth Lederle (SE);</li>\n      <li>Methotrexate &rdquo;Lederle&rdquo; (HU);</li>\n      <li>Methotrexate[inj.] (HR, IT);</li>\n      <li>Methotrexato (AR, EC);</li>\n      <li>Methox (BD);</li>\n      <li>Metodik (AR);</li>\n      <li>Metoject (CZ, DK, ES, FR, HR, IE, RO, SK);</li>\n      <li>Metotreksat (HR);</li>\n      <li>Metotressato Teva (IT);</li>\n      <li>Metotrexato (CL);</li>\n      <li>Metotrexato DBL (IT);</li>\n      <li>Metrex (LK, PY);</li>\n      <li>Mexat (CO);</li>\n      <li>Midu (CN);</li>\n      <li>Mtrex (BD);</li>\n      <li>MTX Hexal (LU);</li>\n      <li>Neotrexate (IN);</li>\n      <li>Novatrex (FR);</li>\n      <li>Onkomet (TH);</li>\n      <li>Otaxem (MX);</li>\n      <li>P&amp;U Methotrexate (ZA);</li>\n      <li>Pterin (PH);</li>\n      <li>Quinux (ES);</li>\n      <li>Reumatrex (PE);</li>\n      <li>Sanotrexat (ID);</li>\n      <li>Texate (MX);</li>\n      <li>Trexan (EE, FI, HN, HU, LT, PL, RU, SG, TR, TW);</li>\n      <li>Trexol (LK);</li>\n      <li>Trexonate (BD);</li>\n      <li>Trexxol (ET);</li>\n      <li>Trixilem (CL, MX, TH);</li>\n      <li>Unitrexates (VN);</li>\n      <li>Viztreksat (UA);</li>\n      <li>Xantromid (PY);</li>\n      <li>Zexate (ET, PH, UY, VE, VN, ZW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    ACOG Practice Bulletin. Clinical Management Guidelines of Obstetrician-Gynecologists. Number 67, October 2005. &ldquo;Medical Management of Abortion,&rdquo; <i>Obstet Gynecol</i>, 2005, 106(4):871-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/16199653/pubmed\" target=\"_blank\" id=\"16199653\">16199653</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Asselin BL, Devidas M, Wang C, et al. Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404). <i>Blood</i>. 2011;118(4):874-883.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/21474675/pubmed\" target=\"_blank\" id=\"21474675\">21474675</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bacci G, Briccoli A, Rocca M, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. <i>Ann Oncol</i>. 2003;14(7):1126-1134.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/12853357/pubmed\" target=\"_blank\" id=\"12853357\">12853357</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bacci G, Ferrari S, Bertoni F, et al. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. <i>J Clin Oncol</i>. 2000;18(24):4016-4027.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/11118462/pubmed\" target=\"_blank\" id=\"11118462\">11118462</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barnhart KT, &quot;Clinical Practice. Ectopic Pregnancy,&quot; <i>N Engl J Med</i>, 2009, 361(4):379-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/19625718/pubmed\" target=\"_blank\" id=\"19625718\">19625718</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bezabeh S, Mackey AC, Kluetz P, Jappar D, Korvick J. Accumulating evidence for a drug-drug interaction between methotrexate and proton pump inhibitors. <i>Oncologist</i>. 2012;17(4):550-554.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/22477728/pubmed\" target=\"_blank\" id=\"22477728\">22477728</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bleyer WA, Coccia PF, Sather HN, et al, &ldquo;Reduction in Central Nervous System Leukemia With a Pharmacokinetically Derived Intrathecal Methotrexate Dosage Regimen,&rdquo; <i>J Clin Oncol</i>. 1983;1(5):317-325.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/6366138/pubmed\" target=\"_blank\" id=\"6366138\">6366138</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bonadonna G, Valagussa P, Moliterni A, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. <i>N Engl J Med</i>. 1995;332(14):901-906.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/7877646/pubmed\" target=\"_blank\" id=\"7877646\">7877646</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Braun J, K&auml;stner P, Flaxenberg P, et al, &quot;Comparison of the Clinical Efficacy and Safety of Subcutaneous Versus Oral Administration of Methotrexate in Patients With Active Rheumatoid Arthritis: Results of a Six-Month, Multicenter, Randomized, Double-Blind, Controlled, Phase IV Trial,&quot; <i>Arthritis Rheum</i>, 2008, 58(1):73-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/18163521/pubmed\" target=\"_blank\" id=\"18163521\">18163521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chao NJ, Schmidt GM, Niland JC, et al, &ldquo;Cyclosporine, Methotrexate, and Prednisone Compared with Cyclosporine and Prednisone for Prophylaxis of Acute Graft-versus-Host Disease,&rdquo; <i>N Engl J Med</i>, 1993, 329(17):1225-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/8413388/pubmed\" target=\"_blank\" id=\"8413388\">8413388</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chao NJ, Snyder DS, Jain M, et al, &ldquo;Equivalence of 2 Effective Graft-Versus-Host Disease Prophylaxis Regimens: Results of a Prospective Double-Blind Randomized Trial,&rdquo; <i>Biol Blood Marrow Transplant</i>, 2000, 6(3):254-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/10871150/pubmed\" target=\"_blank\" id=\"10871150\">10871150</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chi SN, Gardner SL, Levy AS, et al. Feasibility and response to induction chemotherapy intensified with high-dose methotrexate for young children with newly diagnosed high-risk disseminated medulloblastoma. <i>J Clin Oncol</i>. 2004;22(24):4881-4887.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/15611503/pubmed\" target=\"_blank\" id=\"15611503\">15611503</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dadlani C, Orlow SJ. Treatment of children and adolescents with methotrexate, cyclosporine, and etanercept: review of the dermatologic and rheumatologic literature.<i> J Am Acad Dermatol</i>. 2005;52:316-340.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/15692480/pubmed\" target=\"_blank\" id=\"15692480\">15692480</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    deJager MEA, deJong EMGJ, van de Kerkhof PCM, et al. Efficacy and safety of treatments for childhood psoriasis: a systematic literature review. <i>J Am Acad Dermatol </i>. 2010;62:1013-1030.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/19900732/pubmed\" target=\"_blank\" id=\"19900732\">19900732</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    deLemos ML, Monfared S, Denyssevych T, et al. &ldquo;Evaluation of Osmolality and pH of Various Concentrations of Methotrexate, Cytarabine, and Thiotepa Prepared in Normal Saline, Sterile Water for Injection, and Lactated Ringer's Solution for Intrathecal Administration,&rdquo; <i>J Oncol Pharm Pract</i>, 2009, 15(1):45-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/18772215/pubmed\" target=\"_blank\" id=\"18772215\">18772215</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DeWitt EM, Kimura Y, Beukelman T, et al. Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. <i>Arthritis Care Res (Hoboken)</i>. 2012;64(7):1001-1010.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/22290637/pubmed\" target=\"_blank\" id=\"22290637\">22290637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dreyer ZE, Hilden JM, Jones TL, et al. Intensified chemotherapy without SCT in infant ALL: results from COG P9407 (Cohort 3). <i>Pediatr Blood Cancer</i>. 2015;62(3):419-426.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/25399948/pubmed\" target=\"_blank\" id=\"25399948\">25399948</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Sung L, et al; Pediatric Oncology Group of Ontario. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2011;57(2):191-198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/21465637/pubmed\" target=\"_blank\" id=\"21465637\">21465637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Feldman BM, Rider LG, Reed AM, et al. Juvenile Dermatomyositis and other idiopathic inflammatory myopathies of childhood. <i>Lancet</i>. 2008;371(9631):2201-2212.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/18586175/pubmed\" target=\"_blank\" id=\"18586175\">18586175</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ferrari S, Smeland S, Mercuri M, et al. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. <i>J Clin Oncol</i>. 2005;23(34):8845-8852.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/16246977/pubmed\" target=\"_blank\" id=\"16246977\">16246977</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Floyd J, Mirza I, Sachs B, et al, &ldquo;Hepatotoxicity of Chemotherapy,&rdquo; <i>Semin Oncol</i>, 2006, 33(1):50-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/16473644/pubmed\" target=\"_blank\" id=\"16473644\">16473644</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Foeldvari I, Wierk A. Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. <i>J Rheumatol</i>. 2005;32(2):362-365.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/15693100/pubmed\" target=\"_blank\" id=\"15693100\">15693100</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. <i>J Clin Oncol</i>. 1992;10(8):1245-1251.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/1634913/pubmed\" target=\"_blank\" id=\"1634913\">1634913</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gahart BL and Nazareno AR, <i>2014 Intravenous Medications: A Handbook for Nurses and Health Professionals</i>, 30th ed, St Louis, MO: Elsevier/Mosby, 2014, 780-785.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Garrett AP, Garner EO, Goldstein DP, Berkowitz RS. Methotrexate infusion and folinic acid as primary therapy for nonmetastatic and low-risk metastatic gestational trophoblastic tumors. 15 years of experience. <i>J Reprod Med</i>. 2002;47(5):355-362.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/12063874/pubmed\" target=\"_blank\" id=\"12063874\">12063874</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Glantz MJ, Jaeckle KA, Chamberlain MC, et al, &quot;A Randomized Controlled Trial Comparing Intrathecal Sustained-Release Cytarabine (DepoCyt) to Intrathecal Methotrexate in Patients With Neoplastic Meningitis From Solid Tumors,&quot; <i>Clin Cancer Res</i>, 1999, 5(11):3394-402.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/10589750/pubmed\" target=\"_blank\" id=\"10589750\">10589750</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goldman S, Smith L, Anderson JR, et al. Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report. <i>Leukemia</i>. 2013;27(5):1174-1177.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/22940833/pubmed\" target=\"_blank\" id=\"22940833\">22940833</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goldman S, Smith L, Galardy P, et al. Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children's Oncology Group Report. <i>Br J Haematol</i>. 2014;167(3):394-401.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/25066629/pubmed\" target=\"_blank\" id=\"25066629\">25066629</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goorin AM, Schwartzentruber DJ, Devidas M, et al. Presurgical Chemotherapy Compared With Immediate Surgery and Adjuvant Chemotherapy for Nonmetastatic Osteosarcoma: Pediatric Oncology Group Study POG-8651. <i>J Clin Oncol</i>. 2003;21(8):1574-1580.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/12697883/pubmed\" target=\"_blank\" id=\"12697883\">12697883</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Griggs JJ, Mangu PB, Anderson H, et al, &ldquo;Appropriate Chemotherapy Dosing For Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline,&rdquo;<i> J Clin Oncol</i>, 2012, 30(13):1553-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/22473167/pubmed\" target=\"_blank\" id=\"22473167\">22473167</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grossman SA, Finkelstein DM, Ruckeschel JC, et al, &ldquo;Randomized Prospective Comparison of Intraventricular Methotrexate and Thiotepa in Patients With Previously Untreated Neoplastic Meningitis. Eastern Cooperative Oncology Group,&rdquo; <i>J Clin Oncol,</i> 1993, 11(3):561-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/8445432/pubmed\" target=\"_blank\" id=\"8445432\">8445432</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guardiola E, Peyrade F, Chaigneau L, et al. Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. <i>Eur J Cancer</i>. 2004;40(14):2071-2076.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/15341981/pubmed\" target=\"_blank\" id=\"15341981\">15341981</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Huber AM, Giannini EH, Bowyer SL, et al. Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children's Arthritis and Rheumatology Research Alliance Consensus Conference. <i>Arthritis Care Res (Hoboken)</i>. 2010;62(2):219-225.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/20191521/pubmed\" target=\"_blank\" id=\"20191521\">20191521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute for Safe Medication Practices (ISMP). 2014-2015 Targeted Medication Safety Best Practices for Hospitals. http://www.ismp.org/tools/bestpractices/TMSBP-for-Hospitals.pdf. Accessed March 10, 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jacobson JO, Polovich M, McNiff KK, et al, &quot;American Society of Clinical Oncology/Oncology Nursing Society Chemotherapy Administration Safety Standards,&quot; <i>J Clin Oncol</i>, 2009, 27(32):5469-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/19786650/pubmed\" target=\"_blank\" id=\"19786650\">19786650</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Janus N, Thariat J, Boulanger H, et al. Proposal for Dosage Adjustment and Timing of Chemotherapy in Hemodialyzed Patients. <i>Ann Oncol</i>. 2010;21(7):1395-1403.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/20118214/pubmed\" target=\"_blank\" id=\"20118214\">20118214</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kalb RE, Strober B, Weinstein G, et al, &quot;Methotrexate and Psoriasis: 2009 National Psoriasis Foundation Consensus Conference,&quot; <i>J Am Acad Dermatol</i>, 2009, 60(5):824-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/19389524/pubmed\" target=\"_blank\" id=\"19389524\">19389524</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kantarjian HM, O'Brien S, Smith TL, et al. Results of Treatment With Hyper-CVAD, A Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia. <i>J Clin Oncol</i>. 2000;18(3): 547-561.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/10653870/pubmed\" target=\"_blank\" id=\"10653870\">10653870</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kerr JZ, Berg S, and Blaney SM, &ldquo;Intrathecal Chemotherapy,&rdquo; <i>Crit Rev Oncol Hematol</i>, 2001, 37(3):227-36.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/11248578/pubmed\" target=\"_blank\" id=\"11248578\">11248578</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Khouri IF, Romaguera J, Kantarjian H, et al. Hyper-CVAD and High-Dose Methotrexate/Cytarabine Followed by Stem-Cell Transplantation: An Active Regimen for Aggressive Mantle-Cell Lymphoma. <i>J Clin Oncol</i>. 1998;16(12):3803-3809.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/9850025/pubmed\" target=\"_blank\" id=\"9850025\">9850025</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kintzel PE and Dorr RT, &ldquo;Anticancer Drug Renal Toxicity and Elimination: Dosing Guidelines for Altered Renal Function,&rdquo; <i>Cancer Treat Rev</i>, 1995, 21(1):33-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/7859226/pubmed\" target=\"_blank\" id=\"7859226\">7859226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BF, St. Gemell JW, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 19th ed. Philadelphia, PA: Saunders Elsevier; 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Larsen EC, Devidas M, Chen S, et al. Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: a report from Children's Oncology Group Study AALL0232. <i>J Clin Oncol</i>. 2016;34(20):2380-2388.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/27114587/pubmed\" target=\"_blank\" id=\"27114587\">27114587</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Larson RA, Dodge RK, Burns CP, et al, &ldquo;A Five-Drug Remission Induction Regimen With Intensive Consolidation for Adults With Acute Lymphoblastic Leukemia: Cancer and Leukemia Group B Study 8811,&rdquo; <i>Blood</i>, 1995, 85(8):2025-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/7718875 /pubmed\" target=\"_blank\" id=\"7718875 \">7718875 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Le Deley MC, Guinebreti&egrave;re JM, Gentet JC, et al. SFOP OS94: a randomised trial comparing preoperative high-dose methotrexate plus doxorubicin to high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. <i>Eur J Cancer</i>. 2007;43(4):752-761.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/17267204/pubmed\" target=\"_blank\" id=\"17267204\">17267204</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levine MN, Bramwell VH, Pritchard KI, et al. Randomized Trial of Intensive Cyclophosphamide, Epirubicin, and Fluorouracil Chemotherapy Compared With Cyclophosphamide, Methotrexate, and Fluorouracil in Premenopausal Women With Node-Positive Breast Cancer. National Cancer Institute of Canada Clinical Trials Group. <i>J Clin Oncol</i>. 1998;16(8):2651-2658.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/9704715/pubmed\" target=\"_blank\" id=\"9704715\">9704715</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Li SC, Torok KS, Pope E, et al. Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized scleroderma. <i>Arthrit Care Res</i>. 2012;64(8):1175-1185.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/22505322/pubmed\" target=\"_blank\" id=\"22505322\">22505322</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lin WY, Liu HC, Yeh TC, et al, &ldquo;Triple Intrathecal Therapy Without Cranial Irradiation for Central Nervous System Preventive Therapy in Childhood Acute Lymphoblastic Leukemia,&rdquo; <i>Pediatr Blood Cancer</i>, 2008, 50(3):523-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/17455314/pubmed\" target=\"_blank\" id=\"17455314\">17455314</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mack DR, Young R, Kaufman SS, et al. Methotrexate in patients with Crohn&rsquo;s disease after --mercaptopurine. <i>J Pediatr</i>. 1998;132:830-835.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/9602195/pubmed\" target=\"_blank\" id=\"9602195\">9602195</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mahoney DH Jr, Shuster JJ, Nitschke R, et al. Intensification with intermediate-dose intravenous methotrexate is effective therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study. <i>J Clin Oncol</i>. 2000;18(6):1285-1294.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/10715299/pubmed\" target=\"_blank\" id=\"10715299\">10715299</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Matloub Y, Lindemulder S, Gaynon PS, et al. Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children&rsquo;s Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children&rsquo;s Oncology Group. <i>Blood</i>. 2006;108(4):1165-1173.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/16609069/pubmed\" target=\"_blank\" id=\"16609069\">16609069</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mead GM, Barrans SL, Qian W, et al. A Prospective Clinicopathologic Study of Dose-Modified CODOX-M/IVAC in Patients With Sporadic Burkitt Lymphoma Defined Using Cytogenetic and Immunophenotypic Criteria (MRC/NCRI LY10 Trial). <i>Blood</i>.2008;112(6):2248-2260.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/18612102/pubmed\" target=\"_blank\" id=\"18612102\">18612102</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Menter A, Korman NJ, Elmets CA, et al, &ldquo;Guidelines of Care for the Management of Psoriasis and Psoriatic Arthritis: Section 4. Guidelines of Care for the Management and Treatment of Psoriasis With Traditional Systemic Agents,&rdquo; <i>J Am Acad Dermatol</i>, 2009, 61(3):451-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/19493586/pubmed\" target=\"_blank\" id=\"19493586\">19493586</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meyers PA, Heller G, Healey J, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. <i>J Clin Oncol</i>. 1992;10(1):5-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/1370176/pubmed\" target=\"_blank\" id=\"1370176\">1370176</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. <i>J Clin Oncol</i>. 2005;23(9):2004-2011.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/15774791/pubmed\" target=\"_blank\" id=\"15774791\">15774791</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. <i>J Clin Oncol</i>. 2008;26(4):633-638.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/18235123/pubmed\" target=\"_blank\" id=\"18235123\">18235123</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nash R, Antin J, Karanes C, et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-vs-host disease after marrow transplantation from unrelated donors. <i>Blood</i>. 2000;96(6):2062-2068.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/10979948/pubmed\" target=\"_blank\" id=\"10979948\">10979948</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Comprehensive Cancer Network (NCCN)&reg;, &quot;Clinical Practice Guidelines in Oncology&trade;: Central Nervous System Cancers,&quot; Version 2.2009. Available at: http://www.nccn.org/professionals/physician_gls/PDF/cns.pdf.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pieters R, Schrappe M, De Lorenzo P, et al. A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial. <i>Lancet</i>. 2007;370(9583):240-250.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/17658395/pubmed\" target=\"_blank\" id=\"17658395\">17658395</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ramanan AV, Campbell-Webster N, Ota S, et al. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. <i>Arthritis Rheum</i>. 2005;52(11):3570-3578.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/16255046/pubmed\" target=\"_blank\" id=\"16255046\">16255046</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reiter A, Schrappe M, Tiemann M, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-M&uuml;nster Group Trial NHL-BFM 90. <i>Blood</i>. 1999;94(10):3294-3306.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/10552938/pubmed\" target=\"_blank\" id=\"10552938\">10552938</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ross M, Schmidt GM, Niland JC, et al, &ldquo;Cyclosporine, Methotrexate, and Prednisone Compared With Cyclosporine and Prednisone for Prevention of Acute Graft-vs.-Host Disease: Effect on Chronic Graft-vs.-Host Disease and Long-Term Survival,&rdquo; <i>Biol Blood Marrow Transplant</i>, 1999, 5(5):285-291.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/10534058/pubmed\" target=\"_blank\" id=\"10534058\">10534058</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rufo PA, Denson LA, Sylvester FA, et al. Health supervision in the management of children and adolescents with IBD: NASPGHAN recommendations. <i>J Pediatr Gastroenterol Nutr</i>. 2012;55(1):93-108.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/22516861/pubmed\" target=\"_blank\" id=\"22516861\">22516861</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ruperto N, Pistorio A, Oliveira S, et al. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. <i>Lancet</i>. 2016;387(10019):671-678.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/26645190/pubmed\" target=\"_blank\" id=\"26645190\">26645190</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sandhu BK, Fell JME, Beattie RM, et al. Guidelines for the management of inflammatory bowel disease in children in the United Kingdom. <i>JPGN</i>. 2010;50:S1-S13.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/20081543/pubmed\" target=\"_blank\" id=\"20081543\">20081543</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. <i>Blood</i>. 2000;95(11):3310-3322.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/10828010/pubmed\" target=\"_blank\" id=\"10828010\">10828010</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Seibel NL, Steinherz PG, Sather HN, et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. <i>Blood</i>. 2008;111(5):2548-2555.S<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/18039957/pubmed\" target=\"_blank\" id=\"18039957\">18039957</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Seidemann K, Tiemann M, Schrappe M, et al. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-M&uuml;nster Group Trial NHL-BFM 90. <i>Blood</i>. 2001;97(12):3699-3706.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/11389005/pubmed\" target=\"_blank\" id=\"11389005\">11389005</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Simonini G, Cantarini L, Bresci C, Lorusso M, Galeazzi M, Cimaz R. Current therapeutic approaches to autoimmune chronic uveitis in children. <i>Autoimmun Rev</i>. 2010;9(10):674-683.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/20553975/pubmed\" target=\"_blank\" id=\"20553975\">20553975</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Simonini G, Paudyal P, Jones GT, et al. Current evidence of methotrexate efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach. <i>Rheumatol </i>. 2013;52:825-831.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/22879466/pubmed\" target=\"_blank\" id=\"22879466\">22879466</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stewart JS, Cohen EE, Licitra L, et al. Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck. <i>J Clin Oncol</i>. 2009;27(11):1864-1871.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/19289630/pubmed\" target=\"_blank\" id=\"19289630\">19289630</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stringer E, Bohnsack J, Bowyer SL, et al. Treatment approaches to juvenile dermatomyositis (JDM) across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey. <i>J Rheumatol</i>. 2010;37(9):1953-1961.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/20595275/pubmed\" target=\"_blank\" id=\"20595275\">20595275</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. <i>Cancer</i>. 2006;106(7):1569-1580.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/16502413/pubmed\" target=\"_blank\" id=\"16502413\">16502413</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Turner D, Grossman AB, Rosh J, et al. Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn's disease. <i>Am J Gastroenterol</i>. 2007;102(12):2804-1282.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/18042110/pubmed\" target=\"_blank\" id=\"18042110\">18042110</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Turner D, Levine A, Escher J, et al. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. <i>J Pediatr Gastroenterol Nutrit.</i> 2012;55(3):340-361.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/22773060/pubmed\" target=\"_blank\" id=\"22773060\">22773060</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Visser K, Katchamart W, Loza E, et al, &quot;Multinational Evidence-Based Recommendations for the Use of Methotrexate in Rheumatic Disorders With a Focus on Rheumatoid Arthritis: Integrating Systematic Literature Research and Expert Opinion of a Broad International Panel of Rheumatologists in the 3E Initiative,&quot; <i>Ann Rheum Dis</i>, 2009, 68(7):1086-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/19033291/pubmed\" target=\"_blank\" id=\"19033291\">19033291</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weiner MA, Harris MB, Lewis M, et al. Neoadjuvant high-dose methotrexate, cisplatin, and doxorubicin for the management of patients with nonmetastatic osteosarcoma. <i>Cancer Treat Rep</i>. 1986; 70(12):1431-1432.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/3466693/pubmed\" target=\"_blank\" id=\"3466693\">3466693</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weiss B, Lerner A, Shapiro R, et al. Methotrexate treatment in pediatric Crohn disease patients intolerant or resistant to purine analogues. <i>J Pediatr Gastroenterol Nutr</i>. 2009;48:526-530.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/19412004/pubmed\" target=\"_blank\" id=\"19412004\">19412004</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weiss AH, Wallace CA, Sherry DD. Methotrexate for resistant chronic uveitis in children with juvenile rheumatoid arthritis. <i>J Pediatr</i>. 1998;133(2):266-268.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/9709718/pubmed\" target=\"_blank\" id=\"9709718\">9709718</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Widemann BC, Balis FM, Murphy RF, et al, &quot;Carboxypeptidase-G2, Thymidine, and Leucovorin Rescue in Cancer Patients With Methotrexate-Induced Renal Dysfunction,&quot; <i>J Clin Oncol</i>, 1997, 15(5):2125-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/9164227/pubmed\" target=\"_blank\" id=\"9164227\">9164227</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Widemann BC, Balis FM, Shalabi A, et al, &quot;Treatment of Accidental Intrathecal Methotrexate Overdose With Intrathecal Carboxypeptidase G2,&quot; <i>J Natl Cancer Inst</i>, 2004, 96(20):1557-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/15494606/pubmed\" target=\"_blank\" id=\"15494606\">15494606</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Winkler K, Beron G, Delling G, et al. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. <i>J Clin Oncol</i>. 1988;6(2):329-337.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/2448428/pubmed\" target=\"_blank\" id=\"2448428\">2448428</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Winter SS, Dunsmore KP, Devidas M, et al. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. <i>Pediatr Blood Cancer</i>. 2015;62(7):1176-1183.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/25755211/pubmed\" target=\"_blank\" id=\"25755211\">25755211</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zackheim HS, Kashani-Sabet M, and McMillan A. Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients. <i>J Am Acad Dermatol</i>. 2003;49(5):87387-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methotrexate-pediatric-drug-information/abstract-text/14576667/pubmed\" target=\"_blank\" id=\"14576667\">14576667</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12595 Version 243.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709040\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F194555\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F194556\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1048583\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1048575\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F194526\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F194511\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1048588\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132858\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F194549\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1048587\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F194611\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F194607\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F194534\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F194515\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F9837690\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F194520\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F194552\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F194522\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F194538\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1048582\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F1048586\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F194514\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F194533\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F194537\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F194540\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12595|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">Methotrexate: Drug information</a></li><li><a href=\"topic.htm?path=methotrexate-patient-drug-information\" class=\"drug drug_patient\">Methotrexate: Patient drug information</a></li></ul></div></div>","javascript":null}